8-Day Rally Sends Boston Scientific Stock Up 6.5%
Boston Scientific (BSX) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.5% return. The company has gained about $9.5 Bil in value over the last 8 days, with its current market capitalization at about $156 Bil. The stock remains 17.5% above its value at the end of 2024. This compares with year-to-date returns of 14.6% for the S&P 500.
Boston Scientific’s recent streak is fueled by robust Q3 earnings, outperforming expectations, and upwardly revised 2025 guidance, projecting continued momentum. Analyst upgrades to a consensus “Strong Buy” and strong 27% operational growth in its Urology franchise, boosted by new product approvals, underscore investor confidence.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is not much to fear in BSX stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (see Buy or Sell BSX). Nevertheless, don’t get too attached to BSX stock, even if you love it. Stocks crash. High Quality Portfolio lets you navigate that risk.
For quick background, BSX provides medical devices for interventional specialties, including diagnostics and treatments for gastrointestinal, pulmonary, urological, pelvic, cardiovascular, rhythm, and neuro conditions.
- Stronger Bet Than IDEXX Laboratories Stock: BSX, RMD Deliver More
- BSX, RMD Top IDEXX Laboratories Stock on Price & Potential
- Why BSX, RMD Could Outperform IDEXX Laboratories Stock
- BSX, RMD Look Smarter Buy Than IDEXX Laboratories Stock
- Better Value & Growth: BSX, RMD Lead IDEXX Laboratories Stock
- Pay Less, Gain More: BSX, RMD Top IDEXX Laboratories Stock
Comparing BSX Stock Returns With The S&P 500
The following table summarizes the return for BSX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BSX | S&P 500 |
|---|---|---|
| 1D | 0.8% | -1.7% |
| 8D (Current Streak) | 6.5% | -1.7% |
| 1M (21D) | 7.4% | 1.0% |
| 3M (63D) | 1.8% | 4.5% |
| YTD 2025 | 17.5% | 14.6% |
| 2024 | 54.5% | 23.3% |
| 2023 | 24.9% | 24.2% |
| 2022 | 8.9% | -19.4% |
However, big gains can follow sharp reversals – but how has BSX behaved after prior drops? See BSX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 62 S&P constituents with 3 days or more of consecutive gains and 40 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 28 |
| 4D | 8 | 12 |
| 5D | 15 | 0 |
| 6D | 6 | 0 |
| 7D or more | 6 | 0 |
| Total >=3 D | 62 | 40 |
Key Financials for Boston Scientific (BSX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $14.2 Bil | $16.7 Bil |
| Operating Income | $2.4 Bil | $3.0 Bil |
| Net Income | $1.6 Bil | $1.9 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $5.1 Bil | $5.1 Bil |
| Operating Income | $943.0 Mil | $1.1 Bil |
| Net Income | $797.0 Mil | $755.0 Mil |
While BSX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.